Guanfacine
69 interactions 361 cited referencesGuanfacine is a centrally acting alpha-adrenergic medication used to treat high blood pressure and ADHD symptoms. Read the full Guanfacine drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Contraindicated
Guanfacine Ensitrelvir Increased CYP3A substrates exposure and an increased risk of CYP3A substrates-related adverse effects DetailsMajor
Guanfacine Abametapir Increased exposure of CYP3A4 substrate Details Guanfacine Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Guanfacine Avacopan Tavneos Increased CYP3A4 substrate exposure Details Guanfacine Conivaptan Vaprisol Increased guanfacine exposure Details Guanfacine Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Guanfacine Fexinidazole An increased CYP3A4 substrate exposure Details Guanfacine Fosnetupitant Increased exposure of CYP3A4 substrate Details Guanfacine Iobenguane I 131 Azedra Inaccurate dosimetry calculations or reduced efficacy Details Guanfacine Mifepristone Korlym Increased CYP3A4 substrate exposure Details Guanfacine Netupitant Increased exposure of CYP3A4 substrate Details Guanfacine Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Guanfacine Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Guanfacine Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate DetailsModerate
Guanfacine Amitriptyline Elavil Decreased antihypertensive effectiveness Details Guanfacine Aprepitant Aponvie Increased guanfacine exposure Details Guanfacine Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Guanfacine Atazanavir Reyataz Increased guanfacine exposure Details Guanfacine Boceprevir Increased guanfacine exposure Details Guanfacine Bosentan Decreased guanfacine exposure Details Guanfacine Carbamazepine Carbatrol Decreased guanfacine exposure Details Guanfacine Clarithromycin Biaxin Increased guanfacine exposure Details Guanfacine Cobicistat Tybost Increased guanfacine exposure Details Guanfacine Desipramine Norpramin Decreased antihypertensive effectiveness Details Guanfacine Diltiazem Cardizem Increased guanfacine exposure Details Guanfacine Dronedarone Multaq Increased guanfacine exposure Details Guanfacine Efavirenz Decreased guanfacine exposure Details Guanfacine Enzalutamide Xtandi Decreased guanfacine exposure Details Guanfacine Erythromycin Erythrocin Stearate Increased guanfacine exposure Details Guanfacine Fluconazole Diflucan Increased guanfacine exposure Details Guanfacine Fosaprepitant Emend Injection Increased guanfacine exposure Details Guanfacine Fosphenytoin Cerebyx Decreased guanfacine exposure Details Guanfacine Idelalisib Zydelig Increased guanfacine exposure Details Guanfacine Imatinib Gleevec Increased guanfacine exposure Details Guanfacine Imipramine Decreased antihypertensive effectiveness Details Guanfacine Indinavir Increased guanfacine exposure Details Guanfacine Itraconazole Sporanox Increased guanfacine exposure Details Guanfacine Ketoconazole Extina Increased guanfacine exposure Details Guanfacine Kratom Increased CYP3A substrate exposure Details Guanfacine Letermovir Prevymis Increased guanfacine exposure DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist